Bendamustine in the treatment of chronic lymphocytic leukemia

References

• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med.333, 1052–1057 (1995).
   PubMed Web of Science ®Google Scholar
• Kalil N, Cheson BD. Chronic lymphocytic leukemia. Oncologist4, 352–369 (1999).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukaemia. Blood46, 219–234 (1975).
   PubMed Web of Science ®Google Scholar
• Binet JL, Auguier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer48, 198–216 (1981).
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson B, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood111, 5446–5456 (2008).
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet370, 230–239 (2007).
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343, 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Steurer M, Pall G, Richards S et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat. Rev.32, 377–389 (2006).
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol.23, 4079–4088 (2005).
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukaemia. Blood112, 975–980 (2008).
   PubMed Web of Science ®Google Scholar
• Herold M, Keinert K, Anger G et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin’s disease – a 10-year follow-up. Onkologie22, 310–313 (1999).
   Web of Science ®Google Scholar
• Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle lymphoma: results of a randomized Phase III trial (OSHO #19). J. Cancer Res. Clin. Oncol.132, 105–112 (2006).
   PubMed Web of Science ®Google Scholar
• Pönisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized Phase III study of the East German Study Group of Hematology and Oncology (OSHO). J. Cancer Res. Clin. Oncol.132, 205–212 (2006).
   PubMed Web of Science ®Google Scholar
• Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res.14, 309–317 (2008).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs7, 415–421 (1996).
   PubMed Web of Science ®Google Scholar
• Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev.18, 1272–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Schwänen C, Hecker T, Hübiner G et al.In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia16, 2096–2105 (2002).
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica87, 33–43 (2002).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin. Oncol.29(Suppl. 13), 12–14 (2002).
   PubMed Web of Science ®Google Scholar
• Rasschaert M, Schrijvers D, Van den Brande J et al. A Phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. Br. J. Cancer96, 1692–1698 (2007).
   PubMed Web of Science ®Google Scholar
• Rasschaert M, Schrijvers D, Van den Brande J et al. A Phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs18, 587–595 (2007).
   PubMed Web of Science ®Google Scholar
• Chovan JP, Li F, Yu E, Ring SC. Metabolic profile of [(14)C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. Drug Metab. Dispos.35, 1744–1753 (2007).
   PubMed Web of Science ®Google Scholar
• Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol.127, 48–54 (2001).
   PubMed Web of Science ®Google Scholar
• Aivado M, Schulte K, Henze L, Burger J, Finke J, Hass R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin. Oncol.4(Suppl. 13), 19–22 (2002).
   Google Scholar
• Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chromic lymphocytic leukemia: results of a Phase I/II study of the German CLL Study Group. Haematologica90, 1357–1364 (2005).
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pretreated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J. Cancer Res. Clin. Oncol.132, 99–104 (2005).
   PubMed Web of Science ®Google Scholar
• Köppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma45, 911–913 (2004).
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s-lymphomas. J. Cancer Res. Clin. Oncol.128, 603–609 (2002).
   PubMed Web of Science ®Google Scholar
• Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk. Lymphoma45, 2445–2449 (2004).
   PubMed Web of Science ®Google Scholar
• Niederle N, Balleisen L, Heit W et al. Bendamustine vs. fludarabine as second-line treatment for patients with chronic lymphocytic leukemia – first interim results of a randomized study. Ann. Oncol.19(Suppl. 4), iv194 (2008) (Abstract 379).
   Google Scholar
• Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood112, (2008) (Abstract 330).
   Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia: results of an international Phase III study. Blood110, (2007) (Abstract 2043).
   Google Scholar
• Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood8, 2319–2325 (2001).
   Google Scholar
• Johnson S, Smith AG, Löffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet347, 1432–1438 (1996).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood96, 2723–2729 (2000).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood107, 885–891 (2006).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol.25, 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Wendtner CM et al. Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a meta-analysis of two Phase III trials of the German CLL study group (GCLLSG). Blood106(11 Suppl.), (2005) (Abstract 717).
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood112, (2008) (Abstract 325).
   Google Scholar
• Ferrajoli A, O’Brien S, Wierda W et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk. Lymphoma46(Suppl. 1), S86 (2005) (Abstract 95).
   Google Scholar
• Eichhorst BF, Busch R, Stauch M et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients with advanced chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG). Blood110, (2007) (Abstract 629).
   Google Scholar
• Morrison VA, Rai KR, Peterson BL et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil in infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B9011. J. Clin. Oncol.19, 3611–3621 (2001).
   PubMed Web of Science ®Google Scholar